0001104659-21-130030.txt : 20211026
0001104659-21-130030.hdr.sgml : 20211026
20211026170633
ACCESSION NUMBER: 0001104659-21-130030
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211026
FILED AS OF DATE: 20211026
DATE AS OF CHANGE: 20211026
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Merck KGaA
CENTRAL INDEX KEY: 0001764133
STATE OF INCORPORATION: 2M
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40925
FILM NUMBER: 211349473
BUSINESS ADDRESS:
STREET 1: FRANKFURTER STR. 250
CITY: DARMSTADT
STATE: 2M
ZIP: 64293
BUSINESS PHONE: 004961517245950
MAIL ADDRESS:
STREET 1: FRANKFURTER STR. 250
CITY: DARMSTADT
STATE: 2M
ZIP: 64293
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xilio Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840233
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 851623397
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-833-1027
MAIL ADDRESS:
STREET 1: 828 WINTER STREET
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
tm2130646-26_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-10-26
1
0001840233
Xilio Therapeutics, Inc.
XLO
0001764133
Merck KGaA
FRANKFURTER STRASSE 250
DARMSTADT
2M
64293
GERMANY
0
0
1
0
Common Stock
2021-10-26
4
C
0
416060
A
416060
I
See Footnote
Common Stock
2021-10-26
4
C
0
264765
A
680825
I
See Footnote
Series B Preferred Stock
2021-10-26
4
C
0
3952568
D
Common Stock
416060
0
I
See Footnote
Series C Preferred Srock
2021-10-26
4
C
0
2515271
D
Common Stock
264765
0
I
See Footnote
The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
The shares are held directly by Merck Ventures B.V. Merck Ventures B.V. is a wholly owned indirect subsidiary of Merck KGaA, a publicly traded company. Merck KGaA may be deemed to have sole voting and dispositive power with respect to the shares held by Merck Ventures B.V.
The Series C Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on a 9.5:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series C Preferred Stock had no expiration date.
/s/ Christian Uhrich, Authorized signatory of Merck KGaA, Darmstadt, Germany
2021-10-26
/s/ Dariush Bahreini, Authorized signatory of Merck KGaA, Darmstadt, Germany
2021-10-26